Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Post Marketing, Prospective, Observational Cohort Study to Investigate Safety and Effectiveness of Alvocade® in Iranian Patients With Multiple Myeloma

NCT06012383 is registered in ClinicalTrials.gov with NanoAlvand as lead sponsor.

NCT NCT06012383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06012383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Post Marketing, Prospective, Observational Cohort Study to Investigate Safety and Effectiveness of Alvocade® in Iranian Patients With Multiple Myeloma
Lead sponsor
NanoAlvand
Phase
Observational
Overall status
Completed
Start date
July 31, 2016
Completion date
December 31, 2022
Enrollment
57 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, refractory